Gilead Sciences' MAA for bictegravir/emtricitabine/tenofovir alafenamide FDC validated by EMA July 14, 2017
Gilead Sciences submits NDA in U.S. for bictegravir/emtricitabine/tenofovir alafenamide June 13, 2017
Researchers develop a novel assay to quantify inducible, replication competent latent HIV-1 June 6, 2017
U.S. and E.U. submissions made for dolutegravir/rilpivirine single-tablet regimen for HIV-1 June 2, 2017
Four phase III studies of bictegravir/emtricitabine/tenofovir alafenamide meet primary endpoints May 31, 2017
RSS